Aroa Biosurgery study demonstrates low infection rates across 411 reconstruction patients
A peer reviewed analysis of 411 patients in the MASTRR Registry demonstrated low infection rates using Myriad bioscaffolds during complex soft tissue reconstruction procedures
Aroa Biosurgery Limited has released interim results from its MASTRR Registry study, demonstrating remarkably low infection rates among 411 patients undergoing soft tissue reconstruction in 10 US centers. The study, published in Advances in Therapy, evaluated Myriad Matrix™ and Myriad Morcells™ bioscaffolds in complex cases, with 59% of patients classified as ASA Class III or IV.
Despite the challenging patient population, deep tissue infection occurred in only 0.7% of patients and superficial infection in 2.9%, with no infections linked to Myriad products. Aroa CEO Brian Ward highlighted this as a significant milestone for Myriad and the MASTRR Registry, providing a comprehensive dataset of 411 patients and 474 defects.
The favourable infection profile compared favorably with other bioscaffolds, potentially benefiting healthcare providers managing complex soft tissue defects. The MASTRR Registry continues to enroll patients and aims to support further analyses across multiple surgical specialties.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
